Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10039136HBVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS30073496HIVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS30073497HIVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20011278HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029983HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029984HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029985HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029986HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20029987HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TVIS20064469HPVENSG00000147246.10protein_codingHTR2CNoNo3358P28335
TCGA Plot Options
Drug Information
GeneHTR2C
DrugBank IDDB06148
Drug NameMianserin
Target IDBE0000533
UniProt IDP28335
Regulation Typeantagonist
PubMed IDs11004734
CitationsGrinshpoon A, Valevski A, Moskowitz M, Weizman A: Beneficial effect of the addition of the 5-HT 2A/2C and alpha2 antagonist mianserin to ongoing haloperidol treatment in drug-resistant chronically hospitalized schizophrenic patients. Eur Psychiatry. 2000 Sep;15(6):388-90.
GroupsApproved; Investigational
Direct ClassificationDibenzazepines
SMILESCN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21
Pathways
PharmGKBPA134687937
ChEMBLCHEMBL6437